title: Odds still favor Novartis heart failure drug Serelaxin.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratner
mesh_terms: D017277:Drug Approval; D004345:Drug Industry; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D012065:Relaxin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D011994:Recombinant Proteins; C577649:serelaxin protein, human; D012065:Relaxin